level
precis
control
circul
present
highnanomolar
concentr
hla
peripher
tissu
level
significantli
lower
schwab
et
al
coordin
action
sphingosin
kinas
produc
transport
export
extracellular
environ
phosphatas
lyas
degrad
two
intracellular
sphingosin
kinas
sphingosin
kinas
act
phosphoryl
hydroxyl
group
sphingosin
produc
act
upon
intracellular
target
action
receptor
requir
transport
extracellular
environ
one
transport
includ
kawahara
et
al
fukuhara
et
al
mendoza
et
al
kohama
et
al
liu
et
al
degrad
either
revers
dephosphoryl
two
phosphatas
three
nonspecif
lipit
phosphat
phosphatas
kai
et
al
robert
et
al
mandala
irrevers
cleavag
carbon
bond
lyas
zhou
saba
chemic
tool
gener
affect
sever
compon
pathway
other
remain
possibl
target
develop
chemic
modul
sphingosin
kinas
began
discoveri
sphingosin
analog
l
dlthreodihydrosphingosin
n
ndimethylsphingosin
inhibit
activ
sphingosin
kinas
human
platelet
buehrer
bell
yatomi
et
al
sphingosin
deriv
though
potent
exhibit
signific
nonselect
particularli
inhibit
protein
kinas
c
merril
et
al
khan
et
al
numer
sphingosin
analog
includ
receptor
prodrug
use
clinic
treatment
relapsingremit
multipl
sclerosi
also
inhibit
sphingosin
kinas
tonelli
et
al
addit
bind
competit
sever
sphingosin
kinas
inhibitor
also
induc
proteasom
degrad
bind
provid
addit
inhibit
gener
tonelli
et
al
lim
et
al
continu
effort
gener
nanomolar
potenc
isoformselect
antagonist
paugh
et
al
kennedi
et
al
french
et
al
sphingosin
kinas
inhibitor
investig
potenti
treatment
varieti
diseas
particularli
inflammatori
disord
snider
et
al
cancer
maceyka
et
al
sphingosin
kinas
inhibitor
found
reduc
inflamm
tissu
concentr
acut
model
inflammatori
bowel
diseas
main
et
al
select
inhibitor
inhibit
mous
model
allerg
asthma
price
et
al
select
antagon
antagonist
also
demonstr
efficaci
mous
model
inflammatori
crohn
diseas
main
et
al
osteoarthr
fitzpatrick
et
al
sphingosin
kinas
inhibitor
also
antitumor
effect
origin
found
inhibit
leukemia
cell
prolifer
vitro
inhibit
xenograft
tumor
growth
vivo
paugh
et
al
effort
larg
focus
abil
sphingosin
kinas
inhibitor
reduc
prolifer
tumor
cell
also
found
inhibit
breast
cancer
tumor
growth
metastasi
mice
affect
angiogenesi
lymphangiogenesi
nagahashi
et
al
inhibit
demonstr
similar
abil
inhibit
tumor
progress
hepatocellular
carcinoma
xenograft
beljanski
et
al
precis
mechan
chemic
inhibit
sphingosin
kinas
lead
either
suppress
inflamm
tumor
growth
andor
metastasi
remain
unclear
lower
level
inhibit
sphingosin
kinas
may
mani
effect
extracellular
reduc
signal
receptor
intracellular
undetermin
mechan
strub
et
al
may
act
coordin
allevi
patholog
tabl
inhibitor
sphingosin
kinas
effect
reduc
abund
inhibitor
enzym
normal
degrad
also
design
rais
concentr
present
tissu
circul
one
inhibitor
tetrahydroxybutylimidazol
thi
caramel
food
color
high
concentr
act
lyas
inhibitor
elev
concentr
lymphoid
tissu
lead
sequestr
lymphocyt
blood
lymph
similar
treatment
either
agonist
antagonist
schwab
et
al
thi
recent
also
shown
acut
allevi
cardiac
ischemiareperfus
injuri
concomit
increas
tissu
plasma
concentr
bandhuvula
et
al
lyas
inhibit
also
pursu
clinic
treatment
rheumatoid
arthriti
presum
part
sequest
lymphocyt
circul
bagdanoff
et
al
small
molecul
one
addit
tool
develop
modul
avail
sphingomab
monoclon
antibodi
direct
develop
anticanc
drug
anim
model
treat
mice
sphingomab
inhibit
growth
metastasi
tumor
visentin
et
al
ponnusami
et
al
addit
treatment
mice
sphingomab
caus
lymphopenia
despit
increas
blood
lymphat
concentr
much
bound
sphingomab
sensken
et
al
continu
develop
tool
increas
decreas
bind
normal
produc
help
dissect
mani
role
play
physiolog
may
eventu
lead
effect
treatment
human
diseas
previous
mention
phosphoryl
form
highli
potent
yet
nonselect
agonist
valu
low
nanomolar
rang
brinkmann
et
al
analog
sphingosin
phosphoryl
vivo
exclus
gener
paugh
et
al
kharel
et
al
export
extracellular
environ
hisano
et
al
aalr
close
rel
differ
lack
hydroxyl
group
also
effici
phosphoryl
gener
afdr
nonselect
agonist
receptor
jari
et
al
treatment
nonselect
receptor
agonist
lead
rapid
sustain
sequestr
b
cell
blood
lymph
caus
shortlast
bradycardia
mice
human
luo
et
al
budd
et
al
sanna
et
al
immunosuppress
properti
nonselect
receptor
agonist
led
investig
potenti
therapi
transplant
reject
suzuki
et
al
brinkmann
et
al
shimizu
et
al
autoimmun
disord
particularli
multipl
sclerosi
fujino
et
al
thomson
progress
clinic
use
transplant
reject
approv
treatment
relapsingremit
multipl
sclerosi
human
may
contribut
clinic
efficaci
lack
select
make
less
ideal
tool
dissect
role
individu
receptor
play
physiolog
use
help
elucid
differ
downstream
signal
receptor
fate
across
receptor
treatment
cell
express
differ
receptor
lead
rapid
sustain
intern
degrad
even
washout
lead
degrad
graler
goetzl
mullershausen
et
al
given
high
potenc
across
receptor
focu
gener
new
chemic
tool
studi
receptor
focus
improv
select
allow
elucid
role
individu
receptor
play
physiolog
patholog
far
studi
receptor
chemic
genet
due
critic
role
lymphocyt
recircul
agonist
even
direct
screen
hit
gener
abl
achiev
strong
potenc
valu
least
nanomolar
rang
gener
wide
varieti
chemic
scaffold
zhang
et
al
meng
et
al
nakamura
et
al
reed
et
al
sever
shown
fig
readili
appar
mani
agonist
exhibit
long
hydrophob
core
along
polar
charg
headgroup
structur
resembl
amphipath
natur
consist
long
acyl
chain
zwitterion
headgroup
consist
posit
charg
amin
neg
charg
phosphat
group
interact
charg
arginin
glutam
residu
posit
within
bind
pocket
close
extracellular
side
parril
et
al
despit
lack
charg
headgroup
still
reli
interact
activ
jo
et
al
one
rel
uniqu
agonist
possess
charg
highli
polar
headgroup
instead
hydroxyl
group
shown
requir
interact
fact
bind
differ
manner
instead
reli
interact
critic
tryptophan
residu
deep
pocket
potenc
gonzalezcabrera
et
al
hanson
et
al
modif
led
class
arylpropion
acid
activ
picomolar
valu
cahalan
et
al
teijaro
et
al
agonist
vari
significantli
potenc
pharmacokinet
profil
effect
follow
bind
agonist
like
nativ
ligand
caus
intern
cell
surfac
recycl
back
surfac
wherea
other
homolog
afdr
caus
intern
polyubiquitin
degrad
via
proteasom
gonzalezcabrera
et
al
abil
sequest
lymphocyt
blood
lymph
reli
activ
agonist
lead
similar
sequestr
lymphocyt
mice
sanna
et
al
human
treatment
mice
caus
arrest
lymphocyt
close
lymph
node
medullari
sinu
affect
veloc
lymphocyt
found
cortex
wei
et
al
sanna
et
al
receptor
mediat
lymphocyt
sequestr
induc
mice
human
receptor
mediat
bradycardia
elicit
differ
significantli
bradycardia
caus
mice
reli
action
sanna
et
al
agonist
caus
neglig
bradycardia
wherea
agonist
caus
signific
bradycardia
human
activ
g
proteincoupl
inwardli
rectifi
potassium
girk
channel
express
myocyt
gerg
et
al
sinc
activ
inhibit
lymphocyt
recircul
select
agonist
investig
treatment
autoimmun
diseas
potenti
altern
nonselect
agonist
like
agonist
demonstr
efficaci
sever
anim
model
includ
multipl
sclerosi
galiciarosa
et
al
gerg
et
al
gonzalezcabrera
et
al
autoimmun
arthriti
piali
et
al
ulcer
coliti
sanada
et
al
sever
agonist
progress
clinic
trial
focus
multipl
sclerosi
goal
limit
offtarget
effect
result
treatment
howev
possibl
exist
action
receptor
target
sphingosin
kinas
may
aid
efficaci
whether
select
drug
improv
outcom
minim
advers
event
compar
remain
seen
recent
studi
also
found
agonist
compel
effect
inhibit
cytokin
product
follow
infect
influenza
viru
local
treatment
nonselect
receptor
proagonist
aalr
lung
mice
prior
infect
influenza
viru
lead
suppress
viral
specif
cell
respons
suppress
cytokin
product
within
lung
marsolai
et
al
marsolai
et
al
suppress
cytokin
aalr
particular
interest
excess
cytokin
product
implic
pathogen
sever
pandem
influenza
strain
includ
avian
flu
strain
pandem
recent
swine
flu
outbreak
arankal
et
al
lee
et
al
inde
mice
treat
aalr
exhibit
significantli
less
mortal
untreat
mice
follow
infect
influenza
strain
reduct
lethal
synerg
administr
clinic
use
neuraminidas
inhibitor
oseltamivir
walsh
et
al
mechan
aalr
inhibit
cytokin
product
fulli
understood
appear
express
endotheli
cell
play
critic
role
suppress
cytokin
product
well
inhibit
infiltr
innat
immun
cell
lung
teijaro
et
al
abil
agonist
suppress
cytokin
product
may
much
broader
signific
excess
cytokin
product
also
implic
viral
infect
sar
huang
et
al
nagata
et
al
bacteri
infect
pneumococc
pneumonia
fernandezserrano
et
al
unlik
select
agonist
develop
rosen
jo
et
al
urbano
et
al
matt
et
al
fact
vivo
activ
select
agonist
receptor
establish
date
select
agonist
increas
number
matur
oligodendrocyt
obtain
vitro
neonat
rat
cortic
physiolog
effect
determin
vitro
matt
et
al
abund
agonist
comparison
dearth
select
agonist
receptor
larg
due
highclin
relev
may
addit
factor
play
includ
difficulti
actual
discov
gener
compound
fit
specif
bind
pocket
receptor
instanc
thought
significantli
smaller
bind
pocket
may
constrain
amount
interact
agonist
receptor
addit
compound
found
highthroughput
screen
librari
similar
identifi
agonist
agonist
schurer
et
al
publish
agonist
date
fact
alloster
agonist
compet
bind
alloster
agonist
may
provid
altern
rout
discov
select
agonist
receptor
reli
predominantli
interact
deep
within
bind
pocket
rather
interact
charg
residu
locat
near
top
bind
pocket
first
publish
antagonist
discov
follow
find
move
substitu
around
phenyl
ring
para
ortho
caus
switch
agon
antagon
davi
et
al
shown
fig
result
compound
dual
antagonist
though
exhibit
significantli
greater
inhibit
compar
anoth
earli
antagonist
exhibit
similar
ortho
substitut
found
select
activ
could
revers
arrest
lymphocyt
medulla
explant
lymph
node
wei
et
al
howev
initi
antagonist
unsuit
vivo
work
due
instabl
administ
mice
optim
orthosubstitut
analog
eventu
led
replac
phosphat
group
phosphon
group
yield
chiral
antagonist
could
act
vivo
r
enantiom
found
antagonist
enantiom
exhibit
activ
administ
vivo
appear
caus
lymphocyt
sequestr
could
fact
revers
lymphocyt
sequestr
induc
select
agonist
examin
h
treatment
sanna
et
al
equival
phosphon
much
effect
vivo
caus
lymphocyt
sequestr
vivo
revers
sequestr
induc
anoth
agonist
foss
et
al
also
induc
signific
vascular
leakag
lung
exacerb
vegfinduc
leakag
skin
recent
shown
stabil
bind
pocket
allow
crystal
structur
determin
join
lysozym
hanson
et
al
lack
lymphocyt
sequestr
revers
agonistinduc
sequestr
origin
observ
antagonist
led
hypothesi
agonist
act
function
antagonist
express
lymphocyt
direct
agonist
express
endotheli
cell
lead
tighten
junction
inhibit
lymphocyt
egress
recent
work
demonstr
select
antagonist
includ
examin
earlier
timepoint
fact
caus
lymphocyt
sequestr
tarrason
et
al
addit
newer
antagonist
exhibit
higher
potenc
improv
pharmacokinet
properti
induc
lymphocyt
sequestr
sustain
mani
hour
includ
fujii
et
al
seri
biaryl
benzylamin
deriv
angst
et
al
antagonist
structur
differ
previou
antagonist
like
upregul
lymphocyt
cahalan
et
al
fujii
et
al
opposit
effect
seen
agonist
furthermor
abil
sequest
lymphocyt
antagonist
accompani
efficaci
anim
model
allograft
reject
angst
et
al
arthriti
fujii
et
al
multipl
sclerosi
quancard
et
al
cahalan
et
al
abil
antagonist
revers
lymphocyt
sequestr
agonist
timepoint
caus
lymphocyt
sequestr
earlier
timepoint
rais
interest
possibl
regard
competit
within
bind
pocket
downstream
signal
may
area
studi
futur
work
also
determin
whether
antagonist
may
use
potenti
therapeut
autoimmun
diseas
whether
elicit
significantli
wors
advers
event
pulmonari
peripher
edema
compar
agonist
addit
develop
longerlast
antagonist
may
allow
extend
studi
physiolog
patholog
condit
similar
occur
receptor
agonist
studi
use
receptor
antagonist
predominantli
focus
fewer
antagonist
specif
antagonist
wide
use
studi
role
vitro
vivo
particularli
role
play
vascular
physiolog
treatment
vascular
endotheli
cell
improv
barrier
integr
vitro
sanchez
et
al
inhibit
vasoconstrict
excis
arteri
kono
et
al
question
rais
specif
may
effect
independ
salomon
waeber
li
et
al
two
select
antagonist
describ
could
inhibit
coronari
flow
within
isol
rat
heart
vitro
inhibit
bradycardia
vivo
murakami
et
al
abl
compet
nativ
agonist
alloster
agonist
thu
make
bitop
antagonist
although
vivo
action
antagonist
establish
date
jo
et
al
addit
antibodi
describ
block
activ
harri
et
al
antibodi
could
block
lethal
mice
caus
system
lp
treatment
inhibit
growth
breast
cancer
xenograft
provid
potenti
avenu
examin
role
two
distinct
patholog
condit
antagonist
describ
vitro
guerrero
et
al
relev
physiolog
data
publish
date
regard
data
publish
describ
inhibit
select
antagonist
though
patent
applic
file
describ
scaffold
may
act
either
agonist
antagonist
harri
et
al
genet
knockout
sphingosin
kinas
alon
combin
gener
reveal
mani
import
role
gener
physiolog
play
mani
uniqu
role
also
act
somewhat
redundantli
either
mice
viabl
fertil
allend
et
al
kharel
et
al
mizugishi
et
al
mice
display
significantli
reduc
sphk
activ
tissu
particularli
spleen
serum
signific
reduct
observ
mice
also
display
partial
reduct
circul
display
complet
inabl
phosphoryl
howev
mice
defici
render
complet
unabl
produc
begin
exhibit
sever
vascular
hemorrhag
utero
embryo
surviv
past
mizugishi
et
al
lethal
doubl
knockout
mice
circumv
use
mice
constitut
delet
delet
shortli
birth
mani
tissu
use
induc
driven
excis
pappu
et
al
mice
viabl
lack
detect
amount
circul
either
blood
lymph
sourc
found
blood
lymph
distinct
blood
produc
hematopoieit
cell
larg
erythrocyt
lymph
produc
larg
part
lymphat
endotheli
cell
pham
et
al
mice
also
display
signific
basal
vascular
leakag
lung
similar
observ
mice
treat
antagonist
also
display
greatli
increas
sensit
passiv
system
anaphylaxi
sensit
could
larg
revers
agon
camer
et
al
despit
play
somewhat
redund
role
product
circul
delet
either
sphingosin
kinas
mice
effect
play
import
role
inflamm
induc
tnf
tnf
lead
activ
eventu
lead
product
prostaglandin
pettu
et
al
mice
defici
display
significantli
reduc
patholog
sever
experiment
inflammatori
patholog
includ
dextran
sulfat
sodiuminduc
coliti
snider
et
al
arthriti
induc
transgen
express
tnf
baker
et
al
keep
find
mention
earlier
util
select
sphingosin
kinas
inhibitor
find
would
suggest
inhibit
might
good
treatment
diseas
complic
find
mice
display
significantli
increas
pulmonari
edema
respons
either
inflammatori
lp
agonist
peptid
treatment
potenti
lower
amount
abl
activ
normal
act
tighten
vessel
permeabl
recent
work
util
mice
also
suggest
protect
role
follow
ischemia
model
cerebr
ischemia
mice
defici
exhibit
significantli
larger
ischem
lesion
size
h
follow
h
occlus
middl
cerebr
arteri
pfeilschift
et
al
treatment
found
protect
effect
follow
ischem
injuri
protect
abolish
mice
point
toward
protect
function
heart
mice
also
sensit
ischemiareoxygen
injuri
within
heart
exhibit
significantli
larger
infarct
size
vessey
et
al
heart
mice
also
resist
protect
usual
offer
ischem
precondit
addit
exogen
heart
could
offer
protect
oppos
side
metabol
mice
defici
enzym
normal
degrad
gener
studi
role
proper
degrad
play
mice
defici
lyas
encod
gene
display
significantli
reduc
viabil
size
weight
mice
dead
week
age
schmahl
et
al
examin
earli
age
sphingolipid
level
ceramid
sphingomyelin
elev
plasma
level
dihydrosphingosin
ceramid
sphingosin
elev
within
liver
bekta
et
al
mice
also
display
higher
level
cholesterol
serum
exhibit
signific
differ
metabol
mani
lipid
liver
point
toward
import
role
degrad
total
lipid
metabol
broad
elev
sever
sphingolipid
point
potenti
increas
recycl
phosphatas
may
provid
sphingosin
act
substrat
ceramid
synthas
turn
produc
ceramid
hageneuteneu
et
al
mice
defici
lyas
signific
chang
immun
cell
develop
function
reduc
b
cell
number
blood
spleen
exhibit
elev
number
neutrophil
monocyt
blood
elev
proinflammatori
cytokin
serum
allend
et
al
elev
number
neutrophil
increas
proinflammatori
cytokin
could
partial
rescu
also
delet
oppos
irrevers
cleavag
caus
lyas
sever
phosphatas
either
phosphatas
spp
nonspecif
lipid
phosphat
phosphatas
lpp
revers
dephosphoryl
yield
sphingosin
mice
lack
either
specif
spp
describ
date
mice
lack
lpp
gener
mice
defici
describ
defici
clearanc
lysophosphatid
acid
otherwis
phenotyp
normal
tomsig
et
al
likewis
mice
defici
found
viabl
display
signific
phenotyp
date
zhang
et
al
mice
defici
contrast
die
utero
prior
due
gastrul
deficit
ineffici
vascular
yolk
sac
escalantealcald
et
al
condit
delet
special
astrocyt
known
bergmann
glia
lead
alter
metabol
within
cerebellum
result
motor
coordin
deficit
lopezjuarez
et
al
keep
import
role
lymphocyt
develop
induc
delet
lead
ineffici
egress
matur
thymocyt
peripheri
breart
et
al
delet
either
endotheli
cell
epitheli
cell
lead
similar
ineffici
egress
concomit
downregul
would
expect
result
exposur
matur
thymocyt
higher
concentr
delet
also
effect
smooth
muscl
cell
mice
delet
smooth
muscl
exhibit
higher
inflamm
vascular
injuri
panchatcharam
et
al
sinc
produc
larg
insid
cell
must
transport
outsid
cell
order
act
extracellular
target
receptor
thought
transport
part
abc
type
transport
mitra
et
al
sato
et
al
mice
defici
transport
display
chang
circul
recent
separ
transport
identifi
zebrafish
mutant
display
impair
migrat
myocardi
precursor
similar
delet
zebrafish
homolog
kawahara
et
al
sever
group
gener
mice
lack
identifi
inde
transport
delet
lead
defici
thymocyt
egress
b
cell
develop
fukuhara
et
al
hisano
et
al
mendoza
et
al
nagahashi
et
al
nijnik
et
al
express
endotheli
cell
erythrocyt
critic
effici
egress
matur
thymocyt
presenc
signific
concentr
circul
even
absenc
point
toward
level
redund
either
function
abc
type
transport
anoth
transport
yet
determin
origin
identifi
endotheli
differenti
gene
thu
given
gene
name
mice
defici
die
due
vascular
hemorrhag
inabl
smooth
muscl
migrat
enclos
blood
vessel
liu
et
al
mice
lack
sole
endotheli
cell
exhibit
similar
phenotyp
point
critic
role
play
vascular
develop
allend
et
al
express
endotheli
cell
also
play
import
role
develop
matur
vascular
network
particularli
inhibit
excess
sprout
abnorm
sprout
vascular
network
seen
embryo
delet
endotheli
cell
shoham
et
al
similar
increas
branch
seen
mice
delet
induc
shortli
birth
either
tissu
sole
endotheli
cell
jung
et
al
interestingli
express
seem
highest
area
vasculatur
fluid
flow
may
function
sensor
shear
flow
provid
anoth
way
regul
vascular
function
jung
et
al
role
specif
within
vascular
system
discuss
significantli
detail
later
chapter
follow
find
act
agonist
receptor
mani
becam
interest
elucid
function
differ
receptor
lymphocyt
function
delet
develop
cell
either
condit
knockout
bone
marrow
chimer
approach
lead
retent
matur
cell
within
thymu
leav
blood
lymph
deplet
lymphocyt
allend
et
al
matloubian
et
al
mice
b
cell
defici
also
gener
mice
display
impair
egress
immatur
b
cell
bone
marrow
blood
well
decreas
splenic
b
cell
number
allend
et
al
detail
examin
role
lymphocyt
particularli
function
lymphocyt
recircul
posit
lymphocyt
within
lymphoid
tissu
also
follow
later
chapter
addit
critic
role
vascular
lymphocyt
physiolog
play
import
role
within
central
nervou
system
highli
express
within
brain
spinal
cord
across
multipl
cell
type
includ
neuron
astrocyt
agonist
penetr
effici
cn
give
rise
potenti
action
agonist
directli
cn
tissu
mice
delet
astrocyt
refractori
develop
experiment
autoimmun
encephalomyel
eae
mous
model
multipl
sclerosi
wherea
mice
delet
neuron
develop
eae
similar
wildtyp
mice
choi
et
al
interestingli
wherea
wildtyp
mice
eae
display
improv
clinic
score
follow
treatment
mice
eae
lack
astrocyt
display
addit
improv
symptom
follow
treatment
may
also
play
role
inflammatori
pain
agonist
caus
thermal
hyperalgesia
follow
intraplanar
inject
hyperalgesia
depend
part
express
nocicept
neuron
mice
delet
neuron
reduc
hyperalgesia
follow
administr
mair
et
al
like
critic
role
vascular
physiolog
unlik
mice
lack
mice
lack
viabl
maclennan
et
al
ishii
et
al
kono
et
al
howev
defici
mice
deaf
potenti
result
malform
stria
vasculari
inner
ear
defect
hair
cell
herr
et
al
kono
et
al
defici
mice
genet
background
also
exhibit
spontan
seizur
maclennan
et
al
may
play
somewhat
overlap
role
mice
lack
display
sever
embryon
lethal
phenotyp
mice
lack
alon
mice
lack
display
signific
perinat
lethal
ishii
et
al
kono
et
al
mice
defici
also
display
significantli
larger
myocardi
infarct
size
follow
ischemiareperfus
injuri
mice
lack
either
display
differ
point
signific
overlap
function
two
receptor
mean
et
al
anoth
role
within
vascular
system
seen
examin
neovascular
within
eye
defici
mice
display
significantli
less
intravitr
angiogenesi
follow
ischemia
skoura
et
al
condit
knockout
mous
line
yet
report
could
potenti
determin
cell
type
respons
phenotyp
seen
mice
complet
lack
viabl
defici
mice
also
gener
display
signific
abnorm
display
margin
deficit
reproduct
defici
mice
intercross
ishii
et
al
defici
mice
use
show
role
cardiac
physiolog
defici
mice
display
resist
bradycardia
induc
nonselect
proagonist
aalr
sanna
et
al
resist
develop
cardiac
fibrosi
observ
transgen
overexpress
takuwa
et
al
defici
mice
addit
exhibit
lack
vasorelax
caus
show
diminish
vasorelax
induc
inject
highdens
lipoprotein
hdl
presum
result
high
amount
found
within
hdl
nofer
et
al
also
studi
role
immun
system
particularli
margin
zone
mz
b
cell
dendrit
cell
condit
knockout
mous
strain
describ
reciproc
bone
marrow
chimera
experi
adopt
transfer
experi
use
great
success
wildtyp
defici
mice
approach
suggest
express
mz
b
cell
help
properli
posit
within
white
pulp
migrat
mz
b
cell
mediat
larg
part
cinamon
et
al
cinamon
et
al
express
dendrit
cell
regul
migrat
maeda
et
al
mediat
inflamm
induc
variou
pathway
first
defici
mice
display
significantli
less
system
inflammatori
cytokin
product
follow
lp
treatment
wildtyp
mice
reduct
revers
adopt
transfer
wildtyp
dendrit
cell
niessen
et
al
defici
mice
also
display
improv
surviv
compar
wildtyp
mice
follow
lp
treatment
delay
lethal
model
cecal
ligat
punctur
could
revers
ad
exogen
wildtyp
dendrit
cell
defici
mice
also
resist
kidney
ischemia
reperfus
injuri
resist
depend
delet
dendrit
cell
inject
wildtyp
dendrit
cell
defici
mice
prior
injuri
could
lead
revers
protect
grant
defici
mice
bajwa
et
al
last
receptor
describ
likewis
last
vivo
phenotyp
ascrib
delet
like
play
import
role
sever
differ
cell
type
immun
system
knockout
mice
display
impair
termin
differenti
megakaryocyt
lead
deficit
platelet
repopul
follow
administr
antiplatelet
antibodi
observ
differ
platelet
count
normal
condit
golfier
et
al
defici
mice
also
may
help
regul
neutrophil
inflamm
caus
high
level
sphingolipid
lyas
defici
mice
allend
et
al
also
express
dendrit
cell
may
affect
migrat
activ
cell
dendrit
cell
mice
lack
display
acceler
vivo
migrat
drain
lymph
node
defici
dendrit
cell
may
reduc
abil
caus
cell
secret
schulz
et
al
condit
mice
describ
date
defici
mice
like
mice
lack
either
viabl
fertil
knockout
mice
first
describ
context
function
oligodendrocyt
defici
oligodendrocyt
exhibit
process
retract
follow
treatment
jaillard
et
al
note
function
also
found
immun
system
particularli
function
natur
killer
nk
cell
migrat
similar
way
receptor
regul
migrat
type
immun
cell
defici
mice
display
signific
reduct
nk
cell
found
within
blood
spleen
increas
number
bone
marrow
lymph
node
nk
cell
lack
migrat
wildtyp
nk
cell
walzer
et
al
jenn
et
al
mayol
et
al
like
receptor
condit
knockout
mice
yet
describ
mani
genet
modifi
mice
gener
delet
receptor
cell
interest
recent
work
gener
mice
fluorescencetag
version
individu
receptor
replac
receptor
mice
allow
clarif
express
receptor
vivo
flow
cytometri
classic
biochemistri
also
use
intravit
twophoton
microscopi
directli
visual
chang
subcellular
local
receptor
realtim
mice
fuse
fluoresc
protein
egfp
use
studi
treatment
differ
receptor
agonist
antagonist
affect
express
lymphocyt
cahalan
et
al
endotheli
cell
within
central
nervou
system
gonzalezcabrera
et
al
use
visual
differenti
label
distinct
vascular
type
fluoresc
particl
sarkisyan
et
al
critic
identif
endotheli
cell
import
regul
cytokin
product
follow
influenza
infect
teijaro
et
al
similar
approach
also
taken
gener
viabl
mice
express
fuse
fluoresc
protein
mcherri
hugh
rosen
person
commun
mani
potenti
avenu
research
may
deriv
nativ
fluoresc
fusion
protein
mani
may
also
come
abil
immunoprecipit
receptor
use
antibodi
fluoresc
protein
order
determin
posttransl
modif
phosphoryl
polyubiquitin
receptor
well
potenti
determin
associ
protein
mention
previous
becom
rapidli
intern
follow
bind
agonist
lymphocyt
sequestr
induc
agonist
thought
occur
due
intern
mechan
intern
occur
studi
detail
intern
mediat
part
phosphoryl
number
serin
threonin
residu
locat
ctermin
tail
g
proteincoupl
receptor
kinas
grk
lead
bind
clathrinmedi
endocytosi
oo
et
al
recent
knockin
mice
gener
nativ
replac
five
ctermin
serin
mutat
alanin
thu
prevent
intern
thangada
et
al
express
lymphocyt
could
still
intern
follow
either
agonist
treatment
exposur
blood
exhibit
delay
intern
respons
agonist
treatment
compar
wildtyp
resist
intern
parallel
delay
lymphocyt
sequestr
respons
either
agon
lyas
inhibit
express
lymphocyt
show
increas
migrat
toward
high
concentr
suggest
higher
concentr
may
normal
intern
prevent
migrat
similar
knockin
mous
threonin
two
serin
ctermin
tail
replac
alanin
also
gener
display
similar
resist
intern
increas
migrat
chemokin
arnon
et
al
two
knockin
mice
appear
caus
similar
downstream
signal
wildtyp
mice
help
separ
event
follow
agonist
treatment
result
signal
event
may
affect
intern
receptor
pleiotrop
function
complex
biolog
make
delic
system
studi
studi
action
receptor
yield
signific
insight
broad
rang
physiolog
system
continu
excit
area
studi
particularli
relev
human
diseas
despit
rel
recent
discoveri
receptor
modul
biolog
alreadi
progress
clinic
treatment
diseas
progress
aid
significantli
gener
incred
divers
chemic
genet
tool
affect
aspect
biolog
signific
progress
made
sever
area
develop
tool
remain
particularli
gener
select
vivo
chemic
modul
condit
knockout
summari
addit
like
gene
regul
function
yet
found
truli
combin
use
chemic
genet
tool
within
singl
experi
provid
use
conclus
find
function
receptor
continu
develop
refin
hope
continu
aid
understand
physiolog
treatment
human
diseas
